Friday, October 26, 2018

Experimental drug more effective in treating rare kidney disease

New study finds that experimental drug sparsentan is an effective treatment for the rare kidney disease focal segmental glomerulosclerosis, which currently has no FDA-approved therapies.

from Top Health News -- ScienceDaily https://ift.tt/2OSHxYJ
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Common pesticide linked to more than double the risk of Parkinson’s disease

Scientists at UCLA have linked long-term exposure to the pesticide chlorpyrifos with a sharply increased risk of Parkinson’s disease. People...